A number of AGITG members attended this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago (2-6 June).
Following ASCO NEJM Journal Watch Oncology and Hematology have published an article which provides reviews by Associate Editor David H. Ilson, MD, PhD, of key presentations on new Gastro-Intestinal cancer treatments.
The NEJM Journal article – which you can read in full HERE – provides a summary on each of the below:
Duration of Colon Cancer Therapy: 3 or 6 Months?
Vitamin D of Modest Benefit in Metastatic Colon Cancer
Vemurafenib Improves Survival in Metastatic Colorectal Cancer
Radiotherapy Ineffective for Liver Metastases from CRC
Prognostic Factors in Metastatic CRC
Perioperative Chemotherapy for Gastric Cancer: A New Standard
Pembrolizumab Active in Advanced Gastric Cancer
Capecitabine Bests Observation for Biliary Tract Cancer
No Improvement with SIRT for Locally Advanced HCC
Lenvatinib Effective for Unresectable HCC
Full abstracts on each of the above can also be found on the ASCO site HERE